Ph.D., 2009, Indiana Univ.
Systems and network biology approaches to disentangle signaling pathways in cancer development; Computational modeling of how therapeutic compounds function across different genomic backgrounds.
Ph.D., 1992, Univ. of California, Santa Cruz
The molecular dissection of signaling pathways in prostatic cells, the identification of prostate progenitor or stem cells, and understanding epithelial-stromal interactions in normal and abnormal ductal morphogenesis.
M.D./Ph.D., 2001, Univ. of Pennsylvania
Basic and translational research related to lung cancer.
Ph.D., 1996, Univ. of California Los Angeles
Hematopoietic Stem Cell Development and Maintenance: The Role of the "Mixed Lineage Leukemia" Gene in Normal Blood Cell Development, Differentiation and Leukemia.
Ph.D., 1995, Univ. of Rochester
My laboratory studies the parallels between normal development and tumorigenesis/metastasis with a focus on the role of the Six1/Eya transcriptional complex in TGF-beta signaling, epithelial to mesenchymal transition, cancer stem cells, and
Ph.D., 1985, Univ. of California, San Diego
Investigating the role of MAP kinases and specific receptor tyrosine kinases in normal and transformed growth of lung epithelial cells using techniques of molecular and cell biology in lung epithelial cells and human lung cancer cell lines.
Ph.D., 1988, Moscow State Univ.
Epigenetics, phosphoinositide signaling, structural biology, NMR and crystal structures of proteins implicated in cancer, structure based drug design.
Ph.D., 1977, Cornell Univ.
Signaling pathways controlling growth and differentiation of vascular smooth muscle cells; Role of eicosanoids in lung cancer.
Ph.D., 2000, University of Colorado Health Sciences Center
The focus of my lab is to identify novel molecular targets relevant to papillary and anaplastic thyroid cancer (PTC and ATC) with the ultimate goal of advancing these studies to clinical trials for thyroid cancer patients who do not respond to standard treatments.
Ph.D., 1996, Univ. of Bremen
Animal Imaging (MRI, PET, CT); Magnetic Resonance Spectroscopy (MRS) based metabonomics; Cancer Metabolism and Physiology; Anti-Cancer Drugs; Ischemia/Reperfusion in Organs.
Ph.D., 2011, Univ. of Michigan, Ann Arbor
Steroid hormones; anti-estrogen; breast cancer
Professor and Director of the Univ. of Colorado Comprehensive Cancer Center
M.D., 1986, Queen's Univ. Faculty of Health Sciences; Ph.D., 1993, Univ. of Toronto
I'm a physician scientist. Our translational molecular biology laboratory focuses on identifying the molecular mechanisms leading to bladder cancer metastasis and their potential applications to patients with this disease. Our group is at
the forefront of the development of biomarkers and therapeutics in bladder cancer. My clinical practice is limited to bladder cancer management including surgery such as radical cystectomy using state of the art robotic techniques (i.e.
Professor and Chairman
D.Phil., 1990, Univ. of Oxford
Understanding the signaling mechanisms that control apoptosis in cancer development and during the response of tumor cells to cancer therapeutics.
M.D., 1984, Beijing Medical Univ.
TGF-beta signal transduction, molecular mechanisms of cancer development and progression, functions of tumor suppressors and oncogenes.